<DOC>
	<DOCNO>NCT02933372</DOCNO>
	<brief_summary>Varying oral dos Varenicline ( VCN ) , start low dos , administer participant Parkinson 's Disease ( PD ) several day . Positron emission tomography ( PET ) scan administration VCN use determine low oral dose VCN produce adequate brain level VCN . With appropriate oral dose VCN identify , investigator administer VCN PD participant determine VCN improve walk speed measure balance . VCN receive VCN placebo ( fake drug ) 3 week assess effect VCN administration gait speed balance . Participants undergo examination assess intensity Parkinsonism ask question assess mood thinking .</brief_summary>
	<brief_title>Cholinergic Mechanisms Gait Dysfunction Parkinson 's Disease - Proj # 3</brief_title>
	<detailed_description>To demonstrate α4β2* nAChRs appropriate therapeutic target Parkinson 's Disease ( PD ) , necessary study key pharmacokinetic-pharmacodynamic feature α4β2* nAChR context PD brain loss nerve cell produce neurotransmitter acetylcholine , pathologic environment may exhibit unique feature . This personalized medicine approach focus study subgroup PD subject loss nerve cell produce neurotransmitter acetylcholine identify Project II Clinical Resource Core . The investigator assess α4β2* nAChR feature use PET image α4β2* nAChR ligand [ 18-Fluorine ] flubatine , subacute administration α4β2* nAChR partial agonist Varenicline ( VCN ) , laboratory measure gait , balance , attention . The investigator use [ 18-Fluorine ] flubatine PET ass VCN occupancy brain α4β2* nAChRs . Using PET data select appropriate VCN dose , investigator perform pharmacodynamic study subacute VCN administration determine α4β2* nAChR stimulation improve laboratory measure gait function , postural control , attentional function PD subject loss nerve cell produce neurotransmitter acetylcholine .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Cholinergic Agents</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>1 . PD diagnosis base United Kingdom Parkinson 's Disease Society Brain Bank Research Center ( UKPDSBRC ) clinical diagnostic criterion . The investigator enrich cohort recruiting subject modify Hoehn Yahr stag 2 high , duration motor disease 5 year longer , age &gt; 65 year , Postural Instability Gait Disorder ( PIGD ) phenotype . Duration motor disease define time onset motor symptom time entry study . The PIGD phenotype define describe previously . PD subject define cholinergic deficit recruit describe Project II . PD subject cortical cholinergic deficit base 5th percentile cutoff normal control define previously . 2 . Stable dopaminergic replacement therapy 3 month prior enrollment expect maintain stable dopaminergic therapy duration study participation . 1 . Other disorder may resemble PD without dementia , vascular dementia , normal pressure hydrocephalus , progressive supranuclear palsy , multiple system atrophy , corticobasal ganglionic degeneration , toxic cause parkinsonism . Prototypical case distinctive clinical profile , like vertical supranuclear gaze palsy , early severe dysautonomia appendicular apraxia , may differentiate idiopathic PD . The use UKPDSBRC clinical diagnostic criterion PD mitigate inclusion subject atypical parkinsonism participant undergo [ 11Carbon ] dihydrotetrabenazine PET confirm striatal dopaminergic denervation . 2 . Subjects neuroleptic , anticholinergic ( trihexphenidyl , benztropine ) , cholinesterase inhibitor drug . 3 . Current previous ( within last 6 month ) use product medication contain nicotinic agent , include use tobacco product cigarette , cigar , pipe , chew tobacco , etc. , electronic cigarette , overthecounter nicotine patch , chew gum contain nicotine , varenicline . 4 . Evidence stroke mass lesion structural brain imaging ( MRI ) . 5 . Participants magnetic resonance imaging ( MRI ) contraindicate include , limited , pacemaker , presence metallic fragment near eye spinal cord , cochlear implant . 6 . Severe claustrophobia preclude MR PET image 7 . Subjects limited participation research procedures involve ionize radiation . 8 . Pregnancy ( test within 48 hour PET session ) breastfeeding . 9 . Significant risk cardiovascular event . 10 . Active , significant mood disorder .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>